Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print          Annual reports

Thursday 16 July, 2020

Hikma Pharmaceutical

Notice of Results

RNS Number : 2464T
Hikma Pharmaceuticals Plc
16 July 2020

London, July 16, 2020   - Hikma Pharmaceuticals PLC (Hikma), will announce its interim financial results for the six months ended 30 June 2020 on Friday 7 August 2020.

A recording of the presentation will be available on the Company's website at from 8:00am BST. Hikma will also hold a live Q&A conference call for analysts at 9:30am BST, and a recording will be made available on the Company's website later that day.



- ENDS -



Hikma Pharmaceuticals PLC   

Susan Ringdal

EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050



Charles Armitstead                                                                             +44 (0)7703 330 269

Camilla Cunningham                                                                          + 44 (0) 7464 982426



About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and BBB-/stable S&P)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t